−0.0035EUR
−1.10 MEUR
13.70 MEUR
152.78 M
About VISIOMED GROUP
Sector
Industry
CEO
Clement Pacaud
Website
Headquarters
Paris
Founded
2009
ISIN
FR0013481835
FIGI
BBG001RWVJJ1
Visiomed Group SA engages in the development and distribution of healthcare products and services. It operates through the Connected Health, Digitalized Medical Centers, and Other Medical Products and Services segments. The Connected Health segment refers to the strategic activity of the firm which includes telemedicine. The Digitalized Medical Centers segment includes the digitalization of patients' journey that allows taking samples using robotics and connected medical devices and delivering of results using artificial intelligence. The Other Medical Products and Services segment covers historical residual activities of the group and the sales of personal protective and testing equipment. The company was founded by Eric Sebban in June 2007 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ALVMG is 0.1990 EUR — it has decreased by 0.50% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange VISIOMED GROUP stocks are traded under the ticker ALVMG.
One year price forecast for VISIOMED GROUP has a max estimate of 0.7000 EUR and a min estimate of 0.7000 EUR.
Yes, you can track VISIOMED GROUP financials in yearly and quarterly reports right on TradingView.
Like other stocks, ALVMG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VISIOMED GROUP stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VISIOMED GROUP EBITDA is −6.47 M EUR, and current EBITDA margin is −4.38%. See more stats in VISIOMED GROUP financial statements.